C.M.L. Driessen

Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis

Claire Petit, Benjamin Lacas, Jean‐Pierre Pignon et al. · The Lancet Oncology · 2021 · 100 citations · Full text

Adaptive Radiotherapy, Advanced Head, Neck Cancer +6

Chemotherapy-induced peripheral neuropathy and impact on quality of life 6 months after treatment with chemotherapy

Antoinetta J. M. Beijers, Floortje Mols, Wouter Dercksen et al. · The Journal of Community and Supportive Oncology · 2014 · 99 citations

Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients

C.M.L. Driessen, K. M. E. de Kleine-Bolt, A.J.J.M. Vingerhoets et al. · Supportive Care in Cancer · 2011 · 79 citations · Full text

Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study

C.M.L. Driessen, Jan Paul de Boer, Hans Gelderblom et al. · European Journal of Cancer · 2015 · 40 citations

Radiation Medicine, Neck Cancer, Medicine +11

Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma

Maike J.M. Uijen, Gerben Lassche, Adriana C. H. van Engen–van Grunsven et al. · Oral Oncology · 2022 · 24 citations · Full text